1. Academic Validation
  2. 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes

2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes

  • J Med Chem. 2020 Mar 26;63(6):2941-2957. doi: 10.1021/acs.jmedchem.9b01611.
Sanjay Bhattarai 1 Jan Pippel 2 Emma Scaletti 2 Riham Idris 1 Marianne Freundlieb 1 Georg Rolshoven 1 Christian Renn 1 Sang-Yong Lee 1 Aliaa Abdelrahman 1 Herbert Zimmermann 3 Ali El-Tayeb 1 Christa E Müller 1 Norbert Sträter 2
Affiliations

Affiliations

  • 1 PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.
  • 2 Institute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, D-04103 Leipzig, Germany.
  • 3 Institute of Cell Biology and Neuroscience, Goethe-University, D-60438 Frankfurt am Main, Germany.
Abstract

CD73 inhibitors are promising drugs for the (immuno)therapy of Cancer. Here, we present the synthesis, structure-activity relationships, and cocrystal structures of novel derivatives of the competitive CD73 Inhibitor α,β-methylene-ADP (AOPCP) substituted in the 2-position. Small polar or lipophilic residues increased potency, 2-iodo- and 2-chloro-adenosine-5'-O-[(phosphonomethyl)phosphonic acid] (15, 16) being the most potent inhibitors with Ki values toward human CD73 of 3-6 nM. Subject to the size and nature of the 2-substituent, variable binding modes were observed by X-ray crystallography. Depending on the binding mode, large species differences were found, e.g., 2-piperazinyl-AOPCP (21) was >12-fold less potent against rat CD73 compared to human CD73. This study shows that high CD73 inhibitory potency can be achieved by simply introducing a small substituent into the 2-position of AOPCP without the necessity of additional bulky N6-substituents. Moreover, it provides valuable insights into the binding modes of competitive CD73 inhibitors, representing an excellent basis for drug development.

Figures
Products